Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 113 clinical trials
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of muscle invasive bladder

metastasis
radiopharmaceuticals
ct scan
radical cystectomy
bladder tumor
  • 1 views
  • 18 Apr, 2022
  • 1 location
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

invasive bladder cancer (NMIBC). All participants will receive an induction course of gemcitabine/docetaxel instillations followed by maintenance instillations if initial efficacy is seen. In addition to

carcinoma in situ
transurethral resection
intravesical bcg
gemcitabine
hysterectomy
  • 2 views
  • 17 Sep, 2021
  • 1 location
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

The purpose of this study is to find out what effects durvalumab has on bladder cancer, combined with treatment after completion of surgery, chemotherapy and radiotherapy.

neutrophil count
transurethral resection
metastasis
transitional cell carcinoma
gemcitabine
  • 47 views
  • 28 Jun, 2022
  • 39 locations
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment

bladder tumor
carcinoma
measurable disease
invasive bladder cancer
pembrolizumab
  • 0 views
  • 22 Mar, 2022
  • 1 location
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with BCG-unresponsive non-muscle invasive bladder cancer.

  • 0 views
  • 12 Feb, 2021
  • 5 locations
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

The purpose of this study is to investigate the effect synchronous use of nivolumab in addition to chemoradiotherapy in patients withnon-metastatic MIBC who are not candidates for radical cystectomy

radical cystectomy
bladder tumor
cancer
bladder cancer
TURB
  • 9 views
  • 13 Apr, 2022
  • 1 location
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy

autoimmune disease
tumor cells
monoclonal antibody therapy
tumor necrosis factor
radical cystectomy
  • 42 views
  • 09 Aug, 2022
  • 184 locations
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (DURANCE)

DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer

bladder tumor
invasive bladder cancer
neutrophil count
carcinoma
gilbert's syndrome
  • 0 views
  • 30 Apr, 2022
  • 1 location
Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

This is a phase II study of Paclitaxel-binding albumin, Cisplatin as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.

  • 0 views
  • 23 Jan, 2021
  • 1 location
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer (TROJAN)

A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a marker tumour deliberately left following transurethral resection of multiple, papillary NMIBC tumours.

carcinoma in situ
transurethral resection
transitional cell carcinoma
EGFR
bladder tumor
  • 1 views
  • 23 Feb, 2022
  • 1 location